Alexandra M. Binder
Research Subjects
Alexandra M. Binder has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Elizabeth M. Cespedes Feliciano
Division of Research, Kaiser Permanente Northern California, Pleasanton, California
37 shared publications - Catherine Lee
Department of Epidemiology and Biostatistics, University of California, San Francisco , San Francisco, CA
36 shared publications - Jeffrey A. Meyerhardt
Department of Medical Oncology, Dana-Farber Cancer Institute , Boston, MA
36 shared publications - Kathryn Schmitz
Division of Hematology Oncology, University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, 5051 Centre Ave, Suite 5000, Pittsburgh, PA 15232, USA
36 shared publications - Kristin L. Campbell
Department of Physical Therapy Faculty of Medicine University of British Columbia Vancouver British Columbia Canada
36 shared publications - Bette J. Caan
Division of Research, Kaiser Permanente Northern California, Oakland, USA
35 shared publications
Latest Publications
- Open Access
- 27 October 2026
- Published by Elsevier in Environment International
- Vol. 217
Long-term ambient heat and overall mortality among California participants in the Multiethnic Cohort study
- 27 October 2026
- Published by Elsevier in Environment International
- Vol. 217
Open AccessLong-term ambient heat and overall mortality among California participants in the Multiethnic Cohort study
- Open Access
- 23 September 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
Lifestyle and chemotherapy shape functional aging trajectories in older breast cancer survivors and matched comparators
Background: Breast cancer and its treatment may contribute to premature aging, but long-term evidence regarding risk factors for functional decline is limited among the growing population of older survivors. Methods: In the Women’s Health Initiative (n = 45 530; median age at index or diagnosis = 72 years), we compared repeated RAND Short Form 36 (SF-36) physical function scores (0-100) among women with localized (n = 6462) or regional breast cancer (n = 1872) to age-matched, cancer-free comparators (n = 37 196) over 15 years. We tested effect modification by treatment (including agent class), age, and prediagnosis lifestyle behaviors (diet, physical activity, and smoking). Physical performance (grip strength, walking pace) was evaluated in a subset (1045 survivors; 1970 comparators). Results: Survivors experienced acute postdiagnosis declines followed by incomplete recovery leading to a persistent SF-36 deficit relative to age-matched comparators. Regional disease showed larger deficits (−6.8 at year 1; −5.3 at year 10), with the steepest early declines among chemotherapy recipients (-7.1 at year 1), consistent across agents. Grip strength and walking pace showed trends similar to SF-36 deficits. Deficits relative to cancer-free comparators were greater and sustained among older individuals, whereas those aged younger than 70 years showed lesser differences after an early postdiagnosis drop. Among women with lower-risk lifestyle, survivors remained lower than comparators early after diagnosis but showed greater recovery over time; women with higher-risk lifestyles had persistently lower function overall with lesser differences by cancer status. Conclusions: Breast cancer, especially with chemotherapy, was associated with durable functional deficits among older women. Healthier prediagnosis lifestyles are associated with greater functional reserve and better recovery trajectories, suggesting intervention targets for aging survivors.
- 23 September 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
Open AccessLifestyle and chemotherapy shape functional aging trajectories in older breast cancer survivors and matched comparators
Background: Breast cancer and its treatment may contribute to premature aging, but long-term evidence regarding risk factors for functional decline is limited among the growing population of older survivors. Methods: In the Women’s Health Initiative (n = 45 530; median age at index or diagnosis = 72 years), we compared repeated RAND Short Form 36 (SF-36) physical function scores (0-100) among women with localized (n = 6462) or regional breast cancer (n = 1872) to age-matched, cancer-free comparators (n = 37 196) over 15 years. We tested effect modification by treatment (including agent class), age, and prediagnosis lifestyle behaviors (diet, physical activity, and smoking). Physical performance (grip strength, walking pace) was evaluated in a subset (1045 survivors; 1970 comparators). Results: Survivors experienced acute postdiagnosis declines followed by incomplete recovery leading to a persistent SF-36 deficit relative to age-matched comparators. Regional disease showed larger deficits (−6.8 at year 1; −5.3 at year 10), with the steepest early declines among chemotherapy recipients (-7.1 at year 1), consistent across agents. Grip strength and walking pace showed trends similar to SF-36 deficits. Deficits relative to cancer-free comparators were greater and sustained among older individuals, whereas those aged younger than 70 years showed lesser differences after an early postdiagnosis drop. Among women with lower-risk lifestyle, survivors remained lower than comparators early after diagnosis but showed greater recovery over time; women with higher-risk lifestyles had persistently lower function overall with lesser differences by cancer status. Conclusions: Breast cancer, especially with chemotherapy, was associated with durable functional deficits among older women. Healthier prediagnosis lifestyles are associated with greater functional reserve and better recovery trajectories, suggesting intervention targets for aging survivors.
- Open Access
- 3 August 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
Epigenetic aging during adjuvant chemotherapy for colon cancer and modification by a resistance training intervention
Background: Cancer survivors experience excess morbidity and functional decline compared with age-matched individuals without cancer, potentially reflecting acceleration of biological aging during cancer treatment. Epigenetic clocks derived from DNA methylation (DNAm) quantify biological aging, but whether changes in these measures during chemotherapy are modifiable remains unclear. Methods: We evaluated longitudinal changes in epigenetic age acceleration among adults with stage II-III colon cancer undergoing adjuvant chemotherapy in the FORCE randomized trial. Participants were assigned to usual care or resistance training during chemotherapy. Blood DNAm was assessed at baseline and follow-up to derive multiple clocks, including DNAmPhenoAge, GrimAge, and DunedinPACE acceleration measures. Body composition and physical function were measured longitudinally. Linear mixed-effects models estimated changes in epigenetic age acceleration and intervention effects. Results: DunedinPACE acceleration showed the largest increase during treatment (0.70 SD per 6 months, 95% CI = 0.41 to 0.98), followed by GrimAge acceleration (0.29 SD per 6 months, 95% CI = 0.13 to 0.46; approximately 1.2 years). At baseline, higher DunedinPACE acceleration was associated with greater adiposity and poorer physical function. Resistance training attenuated increases in GrimAge acceleration: usual care participants showed significant acceleration (0.45 SD per 6 months, 95% CI = 0.24 to 0.66), whereas intervention participants did not. Changes in epigenetic age acceleration were not strongly associated with body composition or physical function changes. Conclusions: Epigenetic age acceleration increased during colon cancer treatment, with resistance training attenuating GrimAge acceleration. These intervention-responsive changes suggest DNAm-based aging measures may capture treatment-period physiologic changes not fully reflected by body composition or physical function.
- 3 August 2026
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
Open AccessEpigenetic aging during adjuvant chemotherapy for colon cancer and modification by a resistance training intervention
Background: Cancer survivors experience excess morbidity and functional decline compared with age-matched individuals without cancer, potentially reflecting acceleration of biological aging during cancer treatment. Epigenetic clocks derived from DNA methylation (DNAm) quantify biological aging, but whether changes in these measures during chemotherapy are modifiable remains unclear. Methods: We evaluated longitudinal changes in epigenetic age acceleration among adults with stage II-III colon cancer undergoing adjuvant chemotherapy in the FORCE randomized trial. Participants were assigned to usual care or resistance training during chemotherapy. Blood DNAm was assessed at baseline and follow-up to derive multiple clocks, including DNAmPhenoAge, GrimAge, and DunedinPACE acceleration measures. Body composition and physical function were measured longitudinally. Linear mixed-effects models estimated changes in epigenetic age acceleration and intervention effects. Results: DunedinPACE acceleration showed the largest increase during treatment (0.70 SD per 6 months, 95% CI = 0.41 to 0.98), followed by GrimAge acceleration (0.29 SD per 6 months, 95% CI = 0.13 to 0.46; approximately 1.2 years). At baseline, higher DunedinPACE acceleration was associated with greater adiposity and poorer physical function. Resistance training attenuated increases in GrimAge acceleration: usual care participants showed significant acceleration (0.45 SD per 6 months, 95% CI = 0.24 to 0.66), whereas intervention participants did not. Changes in epigenetic age acceleration were not strongly associated with body composition or physical function changes. Conclusions: Epigenetic age acceleration increased during colon cancer treatment, with resistance training attenuating GrimAge acceleration. These intervention-responsive changes suggest DNAm-based aging measures may capture treatment-period physiologic changes not fully reflected by body composition or physical function.
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 6 from Body Composition, Relative Dose Intensity, and Adverse Events among Patients with Colon Cancer
Supplementary Table 6. Sex-Specific Adjusted Associations of Body Composition Measurements (Per SD Increase) with Reduced RDI and Relative Changes (%) in the Number of Moderate and Severe Adverse Events
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 6 from Body Composition, Relative Dose Intensity, and Adverse Events among Patients with Colon Cancer
Supplementary Table 6. Sex-Specific Adjusted Associations of Body Composition Measurements (Per SD Increase) with Reduced RDI and Relative Changes (%) in the Number of Moderate and Severe Adverse Events
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Body Composition, Relative Dose Intensity, and Adverse Events among Patients with Colon Cancer
Supplementary Table 4. The Adjusted Associations of Body Composition Measurements (Per SD Increase) with Reduced RDI Counting for Each Chemotherapy Agent
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Body Composition, Relative Dose Intensity, and Adverse Events among Patients with Colon Cancer
Supplementary Table 4. The Adjusted Associations of Body Composition Measurements (Per SD Increase) with Reduced RDI Counting for Each Chemotherapy Agent
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Body Composition, Relative Dose Intensity, and Adverse Events among Patients with Colon Cancer
Supplementary Table 5. The Adjusted Associations of Body Composition Measurements (Per SD Increase) with Reduced RDI Counting from the Initiation of First Chemotherapy
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Body Composition, Relative Dose Intensity, and Adverse Events among Patients with Colon Cancer
Supplementary Table 5. The Adjusted Associations of Body Composition Measurements (Per SD Increase) with Reduced RDI Counting from the Initiation of First Chemotherapy
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Body Composition, Relative Dose Intensity, and Adverse Events among Patients with Colon Cancer
Supplementary Table 3. The Adjusted Associations of Scaled Body Composition Measurements (Per SD Increase) with Reduced RDI and Relative Changes (%) in the Number of Moderate and Severe Adverse Events
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Body Composition, Relative Dose Intensity, and Adverse Events among Patients with Colon Cancer
Supplementary Table 3. The Adjusted Associations of Scaled Body Composition Measurements (Per SD Increase) with Reduced RDI and Relative Changes (%) in the Number of Moderate and Severe Adverse Events
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Body Composition, Relative Dose Intensity, and Adverse Events among Patients with Colon Cancer
Supplementary Table 1. The Comparisons of Patient Characteristics in All (N = 178), CT (N = 170), DXA (N = 162), and D3Cr (N = 118) Groups
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Body Composition, Relative Dose Intensity, and Adverse Events among Patients with Colon Cancer
Supplementary Table 1. The Comparisons of Patient Characteristics in All (N = 178), CT (N = 170), DXA (N = 162), and D3Cr (N = 118) Groups
- Open Access
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from Body Composition, Relative Dose Intensity, and Adverse Events among Patients with Colon Cancer
Supplementary Table 2. Sex-Specific Standard Deviations of Body Composition Measurements (CT SMA, DXA ALM, D3Cr Muscle, CT TAT, and DXA TBF)
- 26 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from Body Composition, Relative Dose Intensity, and Adverse Events among Patients with Colon Cancer
Supplementary Table 2. Sex-Specific Standard Deviations of Body Composition Measurements (CT SMA, DXA ALM, D3Cr Muscle, CT TAT, and DXA TBF)
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from Body Composition, Relative Dose Intensity, and Adverse Events Among Patients with Colon Cancer
Supplementary Table 1. The Comparisons of Patient Characteristics in All (N = 178), CT (N = 170), DXA (N = 162), and D3Cr (N = 118) Groups
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from Body Composition, Relative Dose Intensity, and Adverse Events Among Patients with Colon Cancer
Supplementary Table 1. The Comparisons of Patient Characteristics in All (N = 178), CT (N = 170), DXA (N = 162), and D3Cr (N = 118) Groups